•   George Lundberg, MD

    As reported in the medical research journal The Lancet, adding the drug pembrolizimab (Keytruda) to chemotherapy increased progression-free survival—both clinically and statistically—for clinical trial participants with advanced breast cancer.

    .

  •   George Lundberg, MD

    As reported by Healio, immunotherapy followed by targeted therapy improved overall survival in a clinical trial with metastatic melanoma patients.

    .

  •   George Lundberg, MD

    This Business Wire press release announces results from a clinical trial indicating that adding the drug olaparib (brand name Lynparza) to treatment for castrate-resistant prostate cancer enhanced disease-free progression, regardless of biomarker status.

    .

  •   George Lundberg, MD

    This scientific editorial article from the Journal of Clinical Oncology discusses results from a clinical trial suggesting that addition of a treatment called transarterial radioembolization to standard treatment was not effective for people with colorectal cancer liver metastases that cannot be removed by surgery.

    .

  •   George Lundberg, MD

    This scientific report from Neuro-Oncology outlines findings from a large, randomized clinical trial showing that the drug veliparib (a kind of drug known as a PARP inhibitor) added to radiotherapy and temozolomide did not improve progression-free survival in unmethylated glioblastoma.

    .

  •   George Lundberg, MD

    As reported by Cancer Network, new results from a phase 3 clinical trial testing the drug rucaparib (Rubraca), which has already been approved by the U.S. Food and Drug Administration, show that it prolongs progression-free survival in some patients with advanced ovarian cancer.

    .

  •   George Lundberg, MD

    Cancer Network reports results from 5 years of follow up for a clinical trial in which the drug olaparib (Lynparza) was given to people who had already been treated for relapsed, high-grade serous, or endometrioid ovarian cancer—including primary peritoneal or fallopian tube cancer. Overall survival data show that olaparib outperformed a placebo drug for these patients, suggesting the possibility that it could be an effective “maintenance therapy.”

    .

  •   George Lundberg, MD

    An academic research paper published in The New England Journal of Medicine reports new results from a phase III, randomized, double-blinded, controlled clinical trial. In the trial, people with esophageal or gastroesophageal junction cancer that had been surgically resected were treated with either a placebo drug or the drug nivolumab. All patients had previously received chemotherapy before resection and had residual disease after surgery. The findings suggest that nivolumab may be beneficial, as median disease-free survival in was doubled (22 versus 11 months) in the nivolumab treated group compared to the placebo group.

    .

  •   George Lundberg, MD

    This scientific research paper published in the journal Cancer Medicine reports that the drug sorafenib has shown some effectiveness against hepatocellular carcinoma in a clinical trial, and that adding vitamin K2 enhanced that effectiveness.

    .

  •   George Lundberg, MD

    A blog post from the National Cancer Institute reports that two clinical trials are showing encouraging results for progression-free survival—and one for overall survival—from treatment with immunotherapy drugs in people with advanced esophageal cancer. 

    .